Illumina Projects China Revenue of $165M+ in 2025 Amid Trade and Regulatory Headwinds

Source: In Vitro Diagnostics Observation

Illumina, a leading company in gene sequencing, recently updated its full-year financial guidance for 2025 and released its first-quarter earnings report.

The company expects an increase of $85 million in tariff costs for the full year, primarily involving products exported from Singapore to the United States.The Trump administration imposed a 10% base tariff on imports from Singapore in April 2025.

CEO Jacob Thaysen stated that the company expects to offset half of the cost impact.

Canaccord Genuity analyst Kyle Mikson noted that Illumina expects the surcharge to bring in an incremental revenue of approximately $40 million.

The company now expects total revenue for 2025 to decrease by 1% to 3% year-over-year at constant exchange rates, compared to the previous forecast of low single-digit growth. This adjustment is primarily due to the import ban on Illumina products imposed by the Chinese government. Meanwhile, the company has lowered its 2025 EPS guidance to $4.20-$4.30 (from the prior expectation of $4.50-$4.65).

Illumina, Inc. expects,China's 2025 revenue will be $1.65 billion to $1.85 billion, with $72 million in confirmed revenue for the first quarter. At the midpoint, China’s full-year revenue will decrease by approximately $125 million year-over-year.

By contrast, the performance of other markets was slightly better: revenue in the Americas was $570 million (a year-on-year decrease of 2%), Europe was $293 million (+5%), and the Asia-Pacific, Middle East, and Africa region was $106 million (-9%).

The company noted that global equipment sales were basically flat, while consumables revenue rose slightly, mainly driven by the increase in clinical sequencing demand.

Illumina also announced that the U.S. Securities and Exchange Commission (SEC)The investigation into its acquisition of subsidiary Grail has been completed, with no violations found.CEO Thaysen stated:"We are pleased to turn the page on this history and continue to focus on future development."

Facing Tariff Impacts and U.S.-China Geopolitical Risks, Illumina Is Maintaining Its Core Business Through Price Adjustments, Cost Reductions, and Regional Realignments. Despite Potential Support from the Clinical Market, Its Global Expansion Is Entering a New Phase of Challenges and Restructuring Amid Compounded Policy and Trade Risks.